Newly designed peptides suggest safer immunotherapies are within reach on May 19, 2026 checkpoint inhibitors engineered peptides immune signaling pathways Immunogenicity (package insert) immunotherapy drugs Peptides Pre-Clinical Model safety profile survival toxicity profile tumor control +
Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach on September 22, 2025 Approved Biosimilars checkpoint inhibitors Immunotherapy for cancer Keytruda Keytruda Qlex Merck patent expiration Solid Neoplasm Subcutaneous Injections United States Food and Drug Administration +
Scancell's Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials on July 23, 2025 Cancer Vaccines checkpoint inhibitors Clinical Trials Immunotherapy iSCIB1 + melanoma Melanoma TRP2 CTL Epitope Vaccine SCIB1 Scancell SCOPE trial +